Drug intelligence / Profile preview

ASP7713

Development stage: Phase 1
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP7713 is an orally administered small molecule drug developed by Astellas Pharma for the treatment of underactive bladder (UAB). It acts as a novel inhibitor of the phosphodiesterase 9 (PDE9) enzyme, with the potential to improve voiding dysfunction by promoting urethral relaxation during the voiding phase. The drug has undergone Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy adult and elderly subjects[1][2][3][6].

Targets

PDE9A (Phosphodiesterase 9A)

Beyond the preview

Go deeper on ASP7713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP7713.

Explore the full profile